hackint0sh/New-Dataset huggingface dataset:
The focus is actually the critical 'first step' before the larger RCT: a pilot and feasibility study on a smaller number of participants with COPD, as an important proof-of-concept that the larger study can, and should, be conducted. conditions: Copd studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 10 type: ESTIMATED name: Urolithin A (Mitopure) name: Placebo measure: Constant Work Rate Exercise Test (CRWET) measure: 6-Minute Walk Test (6MWT) measure: Quadriceps strength measure: Mitochondrial function measure: Muscle histology measure: Tissue microscopy measure: Tissue microscopy measure: Specific protein detection measure: RNA analyses measure: Body composition measure: Body impedance measure: Disease-specific impact on quality of life measure: Burden of disease measure: Cognition measure: Adverse events measure: Differences in dosed missed measure: Blood levels of the intervention sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: McGill University Health Centre status: RECRUITING city: Montréal state: Quebec zip: H4A 3J1 country: Canada name: Bryan A Ross, MD, FRCPC, MSc (Epi, Physiol) role: CONTACT phone: (514) 843-1465 email: bryan.ross@mcgill.ca lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06324201 id: QDOT PAS briefTitle: The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation. acronym: QDOT PAS overallStatus: RECRUITING date: 2024-02-27 date: 2026-03 date: 2028-03 date: 2024-03-21 date: 2024-03-21 name: Heart Rhythm Clinical and Research Solutions, LLC class: OTHER name: Biosense Webster, Inc. briefSummary: Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment to this sub-study per inclusion and exclusion criteria. conditions: Paroxysmal Atrial Fibrillation studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 250 type: ESTIMATED name: Ablation Procedure measure: Safety of the QDOT Micro System use in conjunction with VISITAG SURPOINT Module measure: Effectiveness of the QDOT Micro System use in conjunction with VISITAG SURPOINT Module at 12-months. measure: Effectiveness of the QDOT Micro System use in conjunction with VISITAG SURPOINT Module at 24-months. measure: Effectiveness of the QDOT Micro System use in conjunction with VISITAG SURPOINT Module at 36-months. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centra Health, Inc.dba Stroobants Cardiovascular Center status: RECRUITING city: Lynchburg state: Virginia zip: 24501 country: United States name: Cindy Baumann role: CONTACT name: Mathhew Sackett role: PRINCIPAL_INVESTIGATOR lat: 37.41375 lon: -79.14225 facility: Mercy Health status: RECRUITING city: Janesville state: Wisconsin zip: 53548 country: United States name: Kaitlyn Phetteplace role: CONTACT name: Imdad Ahmed role: PRINCIPAL_INVESTIGATOR lat: 42.68279 lon: -89.01872 hasResults: False
nctId: NCT06324188 id: EASThigh-AFNET 11 briefTitle: Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11) overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2030-02 date: 2030-05 date: 2024-03-21 date: 2024-03-21 name: Atrial Fibrillation Network class: OTHER briefSummary: EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint assessment, multicenter trial (Treatment Strategy trial).
The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity burden (CHA2DS2-VASc ≥4) reduces cardiovascular events (stroke, cardiovascular death, or heart failure events) compared to usual care. conditions: Atrial Fibrillation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE maskingDescription: blinded endpoint assessment whoMasked: OUTCOMES_ASSESSOR count: 2312 type: ESTIMATED name: Early atrial fibrillation ablation name: Usual Care measure: Composite of cardiovascular complications related to AF measure: The primary safety outcome is a composite of all-cause death and serious complications of AF therapy. measure: Number of nights spent in hospital measure: Time from randomisation to first occurrence of each of the individual components of the primary outcome measure: All-cause death measure: Serious adverse events related to AF therapy measure: Time from randomisation to first cardiovascular hospitalisation measure: Number of cardiovascular hospitalisations (over-night stay) measure: Changes in left ventricular ejection fraction measure: Changes in quality of life measure: Changes in quality of life measure: Changes in cognitive function measure: Cardiac rhythm status measure: AF pattern measure: Time from randomisation to first clinical recurrence of AF measure: Time from randomisation to first progression of AF sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Several sites city: Multiple Locations country: Australia facility: Several sites city: Multiple Locations country: Canada facility: Several sites city: Multiple Locations country: Germany facility: Several sites city: Multiple Locations country: Netherlands facility: Several sites city: Multiple Locations country: United Kingdom hasResults: False
nctId: NCT06324175 id: 6353 briefTitle: Spatial Radiogenomics of Ovarian Cancer: Implementation of a Lesion-specific 3D-printed Mould Pipeline in the Clinical Workflow for Image-guided Tissue Multi-sampling of Ovarian Tumours acronym: CO-MOULD overallStatus: RECRUITING date: 2024-02-01 date: 2025-12-31 date: 2026-12-31 date: 2024-03-21 date: 2024-03-21 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: The biological spatial and temporal heterogeneity of High Grade Serous Ovarian Carcinoma (HGSOC) severely impacts the effectiveness of therapies and is a determinant of poor outcomes.
On the other hand, radiomics-derived imaging habitats characterize morphologically distinct tumour areas and are more appropriate for monitoring the changes in the tumour microenvironment over the course of therapy. In order to successfully incorporate the habitat-imaging approach to the clinic, histological and biological validation are crucial. However, histological validation of imaging is not a trivial task, due to issues such as unmatched spatial resolution, tissue deformations, lack of landmarks and imprecise cutting. Patient-specific three-dimensional (3D) moulds are an innovative tool for accurate co-registration between imaging and histology. The aim of this study is to optimize and integrate such an automated computational 3D-mould co-registration approach in the clinical work-flow in patients with HGSOC. The validated radiomics-based tumour habitats will also be used to guide tissue sampling to decipher their underlying biology using genomics analysis and explore novel prediction markers. conditions: Ovarian Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 24 type: ESTIMATED measure: Implementation of the 3D printing pipeline in the clinical setting for recurrent HGSOC measure: Biological validation of spatial radiomics in HGSOC sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Advanced Radiology Center status: RECRUITING city: Roma zip: 00168 country: Italy name: Camilla Panico, MD role: CONTACT phone: +390630158637 lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06324162 id: JagiellonianU Gibas-Stanek briefTitle: Does the Pain Experienced During Orthodontic Treatment and Bracket Removal Depend on the Architecture of the Bracket? acronym: Debonding overallStatus: COMPLETED date: 2021-10-01 date: 2023-05-01 date: 2023-05-01 date: 2024-03-21 date: 2024-03-21 name: Piotr Fudalej class: OTHER briefSummary: The present research aimed to thoroughly investigate the impact of bracket architecture on pain perception during active treatment, debonding, and adhesive removal. conditions: Debonding conditions: Orthodontic Brackets studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 100 type: ACTUAL name: bracket removal pliers, LODI measure: Pain during active treatment measure: Pain during brackets removal measure: Pain on adhesive removal sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Jagiellonian University Collegium Medicum city: Kraków zip: 31-008 country: Poland lat: 50.06143 lon: 19.93658 hasResults: False
nctId: NCT06324149 id: AGE-IT-FRAILTY briefTitle: Age-related Conditions in the Context of Multimorbidity and Frailty: Relative Weight of Frailty in Determining the Course and Outcomes of Different Chronic Diseases and Viceversa acronym: AGE-IT-FRAILTY overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-02-28 date: 2026-04-30 date: 2024-03-21 date: 2024-03-21 name: IRCCS San Raffaele class: OTHER briefSummary: Observational study. Participants of the FRASNET study (9th March 2017, Protocol No. 24/INT/2017) who were evaluated in 2016 and 2017 will be contacted to be re-evaluated with multidimensional visits as part of the present study in order to assess trajectories and biomarkers of frailty and sarcopenia. Moreover, are going to evaluate with the same multidimensional visits patients with mild cognitive impairment and dementia followed up at the Neurologic Unit of the San Raffaele Hospital. conditions: Frailty conditions: Sarcopenia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: completion of scales and questionnaires; venous blood sampling; muscle ultrasound; cardiac ultrasound; electrocardiogram; bioelectrical impedance analysis measure: identify new molecular markers of frailty and sarcopenia measure: evaluate the ability of new markers for frailty, sarcopenia, cognitive impairment sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: San Raffaele Hospital city: Milan country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06324136 id: KIDNEY-PNRR briefTitle: Validation, Implementation, and Cost-analysis of a Strategy for Personalized Diagnosis of Rare Kidney Diseases overallStatus: RECRUITING date: 2023-07-06 date: 2026-07-31 date: 2026-12-30 date: 2024-03-21 date: 2024-03-21 name: Meyer Children's Hospital IRCCS class: OTHER briefSummary: Chronic kidney disease (CKD) affects about 10% of the world population, with high morbidity and mortality. Genetic kidney diseases are increasingly recognized across all age groups and represent over 20% of all the causes of CKD. Accurate diagnosis allows necessary and unnecessary diagnostic procedures to be defined, avoids unnecessary treatments, improves prognosis prediction, identifies other family members for genetic counseling, and defines risks for living donor kidney transplantation. The research group coordinated by the Principal Investigator has recently developed an algorithm for the genetic diagnosis in pediatric and adult patients with CKD. The application of this personalized diagnostic algorithm on a local study led to a global diagnostic yield of 70%, suggesting that this strategy has the potential to substantially improve the diagnostic approach to patients with rare kidney disorders. The aim of this study is to validate and implement these results by extending its application in a multicentric study involving nephrology units that are referral centers for rare kidney diseases at national level. conditions: Chronic Kidney Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 300 type: ESTIMATED name: Implementation of the diagnostic algorithm measure: Implementation of a diagnostic algorithm for personalized diagnosis of rare kidney diseases measure: Analysis of the functional role of variant of unknown clinical significance (VUS) measure: Identification of immunological and/or structural factors in genetic and nongenetic forms. measure: Cost-effectiveness of the diagnostic algorithm. sex: ALL minimumAge: 0 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Meyer Children's Hospital IRCCS status: RECRUITING city: Firenze country: Italy name: Paola Romagnani role: CONTACT lat: 43.77925 lon: 11.24626 facility: Azienda Ospedaliero Universitaria Vanvitelli status: RECRUITING city: Napoli country: Italy name: Miriam Zacchia role: CONTACT lat: 40.85216 lon: 14.26811 facility: Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone status: RECRUITING city: Palermo country: Italy name: Santina Cottone role: CONTACT lat: 38.13205 lon: 13.33561 hasResults: False
nctId: NCT06324123 id: 23C304 briefTitle: Observational Study Aimed at Evaluating the Trend of Neuropathic Pain acronym: NEURATIL overallStatus: RECRUITING date: 2023-06-09 date: 2024-12-31 date: 2024-12-31 date: 2024-03-21 date: 2024-03-25 name: Istituto Auxologico Italiano class: OTHER briefSummary: The present study aims to evaluate the trend of neuropathic pain in patients treated with Peacetil for a period of two months.
Neuropathic pain will me assessed through the Numeric Rating Scale (NRS) questionnaire score. conditions: Neuropathic Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 400 type: ESTIMATED name: Peacetil measure: Change in neuropathic pain after two months of treatment with Peacetil measure: Change in neuropathic pain after one month of treatment with Peacetil sex: ALL minimumAge: 18 Years maximumAge: 82 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto Auxologico Italiano status: RECRUITING city: Milan state: Lombardy zip: 20149 country: Italy name: Luca Maderna, MD role: CONTACT phone: 0261911 email: l.maderna@auxologico.it name: Alberto Doretti, MD role: CONTACT phone: 0261911 phoneExt: 2937 email: neurotrial@auxologico.it lat: 45.46427 lon: 9.18951 facility: ASST Fatebenefratelli Sacco status: NOT_YET_RECRUITING city: Milano zip: 20157 country: Italy name: Fabrizio Gervasoni, MD role: CONTACT email: fabrizio.gervasoni@asst-fbf-sacco.it lat: 45.46427 lon: 9.18951 facility: Fondazione Don Carlo Gnocchi ONLUS status: NOT_YET_RECRUITING city: Milano country: Italy name: Angela Comanducci, MD role: CONTACT email: acomanducci@dongnocchi.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06324110 id: RG1124119 id: NCI-2024-01763 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 20250 type: OTHER domain: Fred Hutch/University of Washington Cancer Consortium id: R01CA284032 type: NIH link: https://reporter.nih.gov/quickSearch/R01CA284032 briefTitle: Evaluating the Impact of Centralized Interventions on Lung Cancer Screening Adherence in Community Settings, ACCELL Trial overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2027-06-30 date: 2027-06-30 date: 2024-03-21 date: 2024-04-10 name: Fred Hutchinson Cancer Center class: OTHER name: National Cancer Institute (NCI) briefSummary: This clinical trial tests the impact of lung cancer screening care coordination interventions implemented at the system-level on lung cancer screening adherence in community settings. Lung cancer remains the leading cause of cancer death in the United States. Although lung cancer screening (LCS) with yearly low-dose chest computed tomography has the potential to decrease lung deaths, the use of this screening technique remains low. In addition, studies have shown that adherence to lung cancer screening in clinical settings is far lower that those found in clinical trials. Improved care coordination services that include comprehensive, system-wide tracking of screening outcomes for all LCS participants, results reporting with direct-to-patient information, direct patient and physician communication, and active reviews of non-adherent patients and stepped support interventions may increase patient adherence to LCS. Coordination services at the system-level may decrease barriers and improve adherence to lung cancer screening in community settings. conditions: Lung Carcinoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 8658 type: ESTIMATED name: Electronic Health Record Review name: Interview name: Patient Navigation measure: Adherence to appropriate follow-up measure: Characteristics associated with adherence to follow up sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fred Hutch/University of Washington Cancer Consortium city: Seattle state: Washington zip: 98109 country: United States name: Tinnie Louie role: CONTACT phone: 206-667-3323 email: tlouie@fredhutch.org name: Matthew Triplette role: PRINCIPAL_INVESTIGATOR lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06324097 id: 2024-357 briefTitle: Diagnostic Value of Endocytoscopy for Colorectal Lesions overallStatus: RECRUITING date: 2024-04-01 date: 2024-05 date: 2024-05 date: 2024-03-21 date: 2024-04-18 name: Hong Xu class: OTHER briefSummary: Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related death worldwide. Colonoscopy is considered the preferred method of screening for colorectal cancer, and resection of colorectal lesions can significantly reduce the incidence and mortality of colorectal cancer. In order to improve the qualitative and quantitative diagnosis of colorectal lesions, many endoscopic techniques, such as image-enhanced endoscopy (IEE), including narrowband imaging (NBI), magnifying endoscopy, pigment endoscopy, confocal laser endoscopy, and endocytoscopy (EC) are applied clinically. The application of EC is intended to achieve the purpose of real-time histopathological endoscopic diagnosis without biopsy. Several studies have shown that EC is effective in identifying the nature of colorectal lesions and judging the depth of invasion in CRC. Based on the endoscopic diagnosis, the endoscopist can determine the treatment plan for the colorectal lesions. The latest EC is an integrated endoscope with a contact light microscopy system with a maximum magnification of 520 x. EC may demonstrate the atypical of gland structure and cells after staining (EC staining mode, along with the use of the EC-NBI mode. The endoscopic diagnosis of the EC staining mode is based on the EC classification (EC-C), used to predict the histopathological diagnosis of colorectal lesions. A prospective randomized trial showed that the diagnostic accuracy was 94.1% by EC-C. However, the diagnostic value of EC-C depends on the operator and may be influenced by the quality of the staining. Meanwhile, the high-quality staining process is time-consuming and tedious. Therefore, EC-NBI seems to be the first choice for EC diagnosis with the advantages of convenient operation and efficient diagnosis. EC-NBI can display the super-amplified surface microvessels of the lesion and provide pathological prediction according to the vessel classification (EC-V). EC-V achieved 99% diagnostic accuracy for hyperplastic polyps and 88.6% for invasive carcinoma. In EC examination, the investigators usually use EC-NBI and EC staining successively to diagnose colorectal lesions, which is believed to improve the diagnostic performance. However, the diagnostic value of increasing EC-staining after EC-NBI examination for predicting the pathological nature of colorectal lesions is still unclear. Therefore, this retrospective study aimed to evaluate the diagnostic value of two different modalities of cell endoscopy for colorectal lesions and to clarify whether additional EC staining after EC-NBI could improve the diagnostic performance of predicting the pathological diagnosis of colorectal lesions.
In the study, the investigators collect clinical information of colorectal lesions which were diagnosed by endoscopic diagnosis (including EC-NBI and EC-staining) and pathological diagnosis. Then, the investigators calculate the accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and high confidence diagnosis rate of EC-C and EC-V classification, respectively. Inter-and intra-observer agreement in the diagnosis of EC-C and EC-V will be calculated. conditions: Colorectal Neoplasms studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 500 type: ESTIMATED name: endocytoscopy measure: sensitivity measure: specificity measure: accuracy measure: positive predictive value measure: negative predictive value measure: inter-observer agreement measure: intra-observer agreement sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: the Department of Gastroenterology and Endoscopy Center, First Hospital of Jilin University status: RECRUITING city: Changchun state: Jilin zip: 130021 country: China name: Mingqing Liu, Doctor role: CONTACT phone: +8613204300453 email: liumq23@mails.jlu.edu.cn name: Hong Xu, Doctor role: PRINCIPAL_INVESTIGATOR name: Mingqing Liu, Doctor role: SUB_INVESTIGATOR name: Nan Zhang, Doctor role: SUB_INVESTIGATOR lat: 43.88 lon: 125.32278 hasResults: False
nctId: NCT06324084 id: 05M201 briefTitle: PATHophysiology of OSteoporosis: Role of Hidden Cortisol Excess and Its Predictors in Bone Fragility acronym: PATHOS overallStatus: RECRUITING date: 2023-04-24 date: 2024-10-24 date: 2025-04-24 date: 2024-03-21 date: 2024-03-21 name: Istituto Auxologico Italiano class: OTHER briefSummary: Osteoporosis is a chronic skeletal disease which leads to a decrease in bone strength which increases the risk of fractures.
Moreover, HidHyCo prevalence seems to be increased in osteoporotic patients. The HidHyCo case finding is of utmost importance. However, given the high prevalence of bone fragility and the relatively low diagnostic accuracy of the currently available tests for the HidHyCo detection, a mass screening for HidHyCo is considered unthinkable. As now, no guidelines are available for addressing the HidHyCo screening in osteoporosis.
Therefore, the aims of the present study are the following: i) to assess the HidHyCo prevalence in a sample of osteoporotic patients; ii) to compare the clinical characteristics between osteoporotic/osteopenic patients with HidHyCo and those without HidHyCo in order to determine the clinical characteristics more frequently associated with the HidHyCo presence and to identify those osteoporotic patients worthy of HidHyCo screening; iii) to further investigate bone quality and turnover in HidHyCo patients, to characterize HidHyco patients from a molecular and genetic point of view and to evaluate the pathogenetic mechanisms explaining the negative effects of endogenous cortisol excess on bone health in these patients and the potential role of the genetic background and of the gut microbiome.